EMA Issues PRIME Report Analyzing Its First Two Years

International Pharmaceutical Regulatory Monitor
A A
The European Medicines Agency issued a report card on the first two years of its Priority Medicines (PRIME) Scheme, highlighting that it has received and processed 177 requests for eligibility for the program that provides early scientific and regulatory support for medicines based on promising preliminary clinical evidence.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor